Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP111921.RAdnNor8ul3T6eoCG7A9ySfpj-eytBqf2W6Bik0s_ASgM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP111921.RAdnNor8ul3T6eoCG7A9ySfpj-eytBqf2W6Bik0s_ASgM130_assertion type Assertion NP111921.RAdnNor8ul3T6eoCG7A9ySfpj-eytBqf2W6Bik0s_ASgM130_head.
- NP111921.RAdnNor8ul3T6eoCG7A9ySfpj-eytBqf2W6Bik0s_ASgM130_assertion description "[In quadruple therapy, rabeprazole-based regimens had better efficacy than esomeprazole-based regimens. CYP2C19 polymorphism also played an important role in quadruple therapy. It seems advisable to change PPI to rabeprazole in second-line quadruple therap]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP111921.RAdnNor8ul3T6eoCG7A9ySfpj-eytBqf2W6Bik0s_ASgM130_provenance.
- NP111921.RAdnNor8ul3T6eoCG7A9ySfpj-eytBqf2W6Bik0s_ASgM130_assertion evidence source_evidence_literature NP111921.RAdnNor8ul3T6eoCG7A9ySfpj-eytBqf2W6Bik0s_ASgM130_provenance.
- NP111921.RAdnNor8ul3T6eoCG7A9ySfpj-eytBqf2W6Bik0s_ASgM130_assertion SIO_000772 20633187 NP111921.RAdnNor8ul3T6eoCG7A9ySfpj-eytBqf2W6Bik0s_ASgM130_provenance.
- NP111921.RAdnNor8ul3T6eoCG7A9ySfpj-eytBqf2W6Bik0s_ASgM130_assertion wasDerivedFrom gad-20150221 NP111921.RAdnNor8ul3T6eoCG7A9ySfpj-eytBqf2W6Bik0s_ASgM130_provenance.
- NP111921.RAdnNor8ul3T6eoCG7A9ySfpj-eytBqf2W6Bik0s_ASgM130_assertion wasGeneratedBy ECO_0000203 NP111921.RAdnNor8ul3T6eoCG7A9ySfpj-eytBqf2W6Bik0s_ASgM130_provenance.